20 articles
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
TONTT2 tests whether erythropoietin dose and timing can be optimized to best preserve vision after traumatic optic neuropathy.
Bilateral theta burst stimulation enhanced neural repair and restored function after stroke in non-human primates through multiple mechanisms.
A post hoc analysis of the DISTAL trial finds EVT plus medical therapy significantly improves brain tissue preservation in hard-to-reach vessel occlusions.
A Japanese RCT shows tenecteplase (0.25 mg/kg) achieves 3x higher early recanalization than low-dose alteplase (0.6 mg/kg) in LVO stroke patients.
After ischemic stroke, a mislocated brain water channel (AQP4) disrupts waste clearance. Blocking AQP4 with TGN-020 corrects its position and restores glymphatic flow.
Italian researchers developed a biosensor to track extracellular vesicles in blood, potentially personalizing stroke rehabilitation.
New research questions the continued use of IV alteplase for stroke treatment, potentially reshaping emergency care protocols.
Deleting or inhibiting astrocytic PERK restores the brain's glymphatic drainage system and dramatically reduces Aβ and tau pathology in AD mouse models.
New research identifies plasma and CSF tau biomarkers that closely mirror tau PET scans, potentially replacing costly brain imaging.
New peptide delivery system restores brain connections and memory function in Alzheimer's models, offering hope for treating cognitive decline.
Synthetic peptide chimeras degrade amyloid-beta across the blood-brain barrier, improving cognition in mice with fewer risks than current immunotherapies.
A randomized trial finds intra-arterial alteplase after successful thrombectomy does not improve outcomes in posterior circulation stroke.
Inhibiting TRPV4 channels in mice restored glymphatic drainage, cut cerebral edema, and improved neurological recovery after ischemic stroke.
Avlayah (tividenofusp alfa-eknm) becomes the first therapy approved to address brain damage in Hunter syndrome, a rare pediatric disorder.
New gene therapy zorevunersen dramatically reduced seizures in children with severe Dravet syndrome epilepsy while improving quality of life.
New research reveals how TSC2 mutations suppress translation of autism and epilepsy genes, offering potential therapeutic targets.
Researchers identify transthyretin (TTR) as a potential biomarker for postoperative cognitive dysfunction, offering new diagnostic hope.
A boy with PLCB1-related epileptic encephalopathy showed improved seizure control and stabilized brain atrophy after high-dose enteral myo-inositol supplementation.
DPCPX treatment enhanced neurogenesis and improved motor/memory function in stroke recovery studies using advanced PET imaging.
